Furthermore, the treatment of CT26 tumor-bearing mice with the shikonin/JQ1-loaded nanosystem efficiently decreased the tumor growth; suppressed the glucose metabolism (as seen by reduced levels of lactate, PKM2, and HIF-1α in the tumor tissue); downregulated the intratumoral PD-L1 expression; and remodeled the TME’s immune configuration (e.g., the promotion of dendritic cell maturation and CD8+ T-cell infiltration, as well as suppression of Treg). The gene discussed is HIF1A; the disease is neoplasm.